Low m6A levels secondary to METTL14 mutation or decreased METTL3 expression are observed in 70% of endometrial cancers, and low m6A is associated with increased activation of oncogenic AKT signaling through translation inhibition of the AKT negative regulator PHLPP2, and mRNA stabilization of the AKT positive regulator mTORC264. This evidence concerns the gene AKT1 and endometrial cancer.